Previous close | 113.10 |
Open | 113.63 |
Bid | 0.00 x 800 |
Ask | 0.00 x 900 |
Day's range | 113.01 - 114.34 |
52-week range | 89.67 - 121.64 |
Volume | |
Avg. volume | 6,195,906 |
Market cap | 198.105B |
Beta (5Y monthly) | 0.72 |
PE ratio (TTM) | 35.92 |
EPS (TTM) | 3.17 |
Earnings date | 16 Oct 2024 - 21 Oct 2024 |
Forward dividend & yield | 2.20 (1.93%) |
Ex-dividend date | 15 Jul 2024 |
1y target est | 124.04 |
ABT made its CGM system Lingo available in the United States. The system can be used by consumers aged 18 years and older who are not on insulin.
Abbott Laboratories launched its newest CGM in the U.S. on Thursday. The biosensor named Lingo is the first-ever for people without diabetes.
According to the average brokerage recommendation (ABR), one should invest in Abbott (ABT). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?